Safety and efficacy of immunosuppressants for recurrent reproductive failure: A systematic review and meta-analysis
Journal of Reproductive Immunology · 2026
DOI: 10.1016/j.jri.2026.104940 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Reproductive Immunology, 2026. Verfasst von Yv Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China; Antibody Research Laboratory, Wuhan Institute of Biologic…. Hauptthemen laut MEDLINE: Abortion, Habitual, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Hospital.
Abstract (Originalsprache)
Recurrent reproductive failure impairs women's health, and the efficacy of immunosuppressants for this condition remains uncertain. This study aimed to explore the clinical application of common immunosuppressive agents including cyclosporine A, tacrolimus, etanercept and adalimumab for recurrent reproductive failure, which covers recurrent spontaneous abortion and recurrent implantation failure after IVF/ICSI, and to assess their efficacy and safety so as to provide evidence-based references for clinical practice. We retrieved eligible randomized controlled trials and cohort studies published from January 1, 2005 to February 28, 2025 from PubMed, Web of Science, CNKI and Wanfang databases, and conducted a systematic review and meta-analysis. This study was registered on PROSPERO (ID: CRD420251057130). A total of 13 randomized controlled trials and 7 cohort studies involving 2266 patients were finally included. Meta-analysis revealed that compared with the control group, immunosuppressive therapy significantly elevated live birth rate (RR=1.33, 95%CI:1.20-1.47, P < 0.00001) and clinical pregnancy rate (RR=1.24, 95%CI:1.11-1.39, P = 0.0001), while lowering miscarriage rate (RR=0.45, 95%CI:0.37-0.54, P < 0.00001). No significant differences were found in the incidence of adverse events (RR=0.96, 95%CI:0.69-1.34, P = 0.83) and birth defect rate (RR=0.63, 95%CI:0.19-2.07, P = 0.45) between the two groups. In conclusion, the above immunosuppressive drugs can improve pregnancy outcomes in patients with recurrent reproductive failure and do not obviously increase adverse reactions and birth defects. Considering the limited quality of existing evidence and potential publication bias, the results should be interpreted cautiously, and the use of these drugs is recommended to be limited to clinical trials until verified by more large-scale and high-quality randomized studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China; Antibody Research Laboratory, Wuhan Institute of Biological Products Co., Ltd., Hubei Provincial Vaccine Technology Innovation…
- Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Electronic address: houning196@163.com.
Förderung
- Shandong Provincial Hospital
Zitieren
APA
Gao, Y., Xu, K., Yang, S., & Hou, N. (2026). Safety and efficacy of immunosuppressants for recurrent reproductive failure: A systematic review and meta-analysis. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2026.104940
Vancouver
Gao Y, Xu K, Yang S, Hou N. Safety and efficacy of immunosuppressants for recurrent reproductive failure: A systematic review and meta-analysis. Journal of Reproductive Immunology. 2026. doi:10.1016/j.jri.2026.104940
BibTeX
@article{Gao2026,
author = {Gao, Yv and Xu, Ke and Yang, Shuangshuang and Hou, Ning},
title = {Safety and efficacy of immunosuppressants for recurrent reproductive failure: A systematic review and meta-analysis},
journal = {Journal of Reproductive Immunology},
year = {2026},
doi = {10.1016/j.jri.2026.104940}
}
EUVIMED